Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT01776840 trial: what clinicians have said so far
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- NCT01776840 ↗
- Completed
- Janssen Research & Development, LLC
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT01776840 (ibrutinib in newly diagnosed mantle cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01776840 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Bendamustine; Rituximab; Ibrutinib; Placebo
- Arms
- Treatment Arm A · Placebo comparator
- Treatment Arm B · Experimental
- Enrollment
- 523
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- Janssen Research & Development, LLC with Pharmacyclics LLC.
- Start
- May 16, 2013
- Primary completion
- Jun 30, 2021
- Results posted
- Yes
- Registry record
- NCT01776840 · updated Jul 8, 2025
Publications
linked from the registry- Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernandez-Rivas JA, Hong X, Kim SJ, Lewis D, Mishima Y, Ozcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. PubMed 35657079